ClinicalTrials.gg
CompletedNCT06797869Updated Sep 10, 2026

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

A Phase 2 interventional study of CagriSema (Cagrilintide B and Semaglutide I) and Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) in Diabetes Mellitus, Type 2 and Diabetic Peripheral Neuropathy, sponsored by Novo Nordisk A/S. Completed at 55 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 4 of them phase 3. cagrilintide · Diabetes Mellitus, Type 2.

Enrollment
12th of 15
142 · median 274
Started
2025
with 1 other
Phase 2
4 of 15
none open now
Registered
10th of 15
by date
Lead sponsor
15 of 15
Novo Nordisk A/S

Among the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 15 studies testing cagrilintide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing cagrilintide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Diabetic Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female.
  • Age 18 years or above at the time of signing the .
  • (BMI) ≥25.0 kilogram per square meter (kg/m\^2) at screening.
  • Diagnosis of type 2 diabetes (T2D) ≥180 days before screening.

    -- For participants on anti-diabetic drugs: Stable daily and/or weekly dose(s) ≥90 days before screening of any of the following anti-diabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose, as judged by the investigator:

    • Treatment with 1-3 marketed oral anti-diabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitors (SGLT2i), thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local guidelines.
    • Treatment with basal or basal-bolus insulin (including premixed insulin formulations) according to local guidelines.
  • ≤10.5 % (91 millimole per mole [mmol/mol]) and ≥6.0 % (42 mmol/mol), as determined by central laboratory at screening.
  • Diagnosis of painful diabetic peripheral neuropathy (pDPN) at screening as well as at the following criteria:

    -- Participant with self-reported pain consistent with pDPN for a minimum of 3 months before screening, as judged by the investigator.

  • Stable pharmacological and non-pharmacological treatment of pain for a minimum of 3 months before screening, in the opinion of the investigator. The treatment regimen should adhere to local guidelines (if available).

Key Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  • Use of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, (DPP-4), or amylin analogue within 60 days before screening.
  • Significant use of opioids, cannabinoids or benzodiazepines within 30 days before screening, in the opinion of the investigator. Significant use is defined as use that renders it unlikely that the participant is able to comply with protocol requirements for discouraged medications.
  • Anticipated initiation or change in concomitant medications (for more than 14 consecutive days during the study) known to affect weight or glucose metabolism (e.g., orlistat, thyroid hormones or oral ).
  • Planned initiation or change in anti-depressant, anti-psychotic or anti-epileptic medication. If participants are already taking such medication, they should have stable and optimised treatment for at least 8 weeks before screening.
  • Presence or history of epilepsy and fibromyalgia.
  • Presence of non-diabetic neuropathies, in the opinion of the investigator.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination and OCT assessment performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • Any other painful medical condition(s) where the pain is significantly more severe than the diabetic peripheral neuropathy pain, as judged by the investigator (participants will not be excluded if the pain is transient in nature).
  • History of suicidal attempt within 5 years before screening
  • Suicidal behaviour within 1 month before screening.
  • Renal impairment with estimated (eGFR) \<30 ml/min/1.73 m2 as determined by central laboratory at screening.
  • Exposure to an medicinal product within 90 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 32 weeks.

    Drug: CagriSema (Cagrilintide B and Semaglutide I)

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to CagriSema (Cagrilintide B + Semaglutide I) subcutaneously once weekly for 32 weeks.

    Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

Interventions

  • DrugCagriSema (Cagrilintide B and Semaglutide I)

    Drug page: Cagrilintide

    Cagrilintide B and Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

  • DrugPlacebo matched to CagriSema (Cagrilintide B and Semaglutide I)

    Placebo matched to Cagrilintide B and Placebo matched to Semaglutide I will be administered subcutaneously using DV3384 pen-injector.

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in weekly average Pain Intensity-Numerical Rating Scale (PI-NRS)

    Measured as score on a scale.

    Time frame: From baseline (week 0) to end of treatment (week 32)

Secondary outcomes

  1. Number of participants reaching ≥30 percentage (%) reduction in PI-NRS

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  2. Time to achieve ≥30% reduction in weekly average PI-NRS

    Measured as days.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  3. Number of participants reaching ≥50 % reduction in PI-NRS

    Measured as count of participants.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  4. Time to achieve ≥50% reduction in weekly average PI-NRS

    Measured as days.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  5. Change in Brief Pain Inventory-Short Form (BPI-SF)

    Measured as score on a scale.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  6. Change in Chronic Pain Sleep Inventory 3-item (CPSI 3)

    Measured as score on a scale.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  7. Change in Michigan Neuropathy Screening Instrument (MNSI)

    Measured as score on a scale.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  8. Change in systolic blood pressure

    Measured as millimeters of mercury (mmHg).

    Time frame: From baseline (week 0) to end of treatment (week 32)

  9. Change in diastolic blood pressure

    Measured as mmHg.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  10. Change in glycated haemoglobin (HbA1c)

    Measured as percentage of HbA1c.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  11. Change in Fasting Plasma Glucose (FPG)

    Measured as millimole per liter (mmol/L).

    Time frame: From baseline (week 0) to end of treatment (week 32)

  12. Relative change in body weight

    Measured as percentage change.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  13. Change in waist circumference

    Measured as centimeter (cm).

    Time frame: From baseline (week 0) to end of treatment (week 32)

  14. Ratio to Baseline in Lipids: Total Cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  15. Ratio to Baseline in Lipids: High-density lipoprotein (HDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  16. Ratio to Baseline in Lipids: Low-density lipoprotein (LDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  17. Ratio to Baseline in Lipids: Very low-density lipoprotein (VLDL) cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  18. Ratio to Baseline in Lipids: Triglycerides

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  19. Ratio to Baseline in Lipids: Free fatty acids

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  20. Ratio to Baseline in Lipids: Non-HDL cholesterol

    Measured as ratio.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  21. Relative change in high sensitivity C-reactive protein (hsCRP)

    Measured as percentage change.

    Time frame: From baseline (week 0) to end of treatment (week 32)

  22. Number of treatment-emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 38)

  23. Number of treatment-emergent serious adverse events (TESAEs)

    Measured as count of events.

    Time frame: From baseline (week 0) to end of study (week 38)

  24. Number of severe hypoglycaemic episodes (level 3) (No specific glucose threshold)

    Severe hypoglycaemia is a severe event characterised by altered mental and/or physical status requiring assistance from another person to actively administer carbohydrates, glucagon, or take other corrective actions to treat hypoglycaemia. Measured as count of episodes.

    Time frame: From baseline (week 0) to end of study (week 38)

  25. Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol/L (54 mg/dL) confirmed by blood glucose meter))

    Measured as count of episodes.

    Time frame: From baseline (week 0) to end of study (week 38)

07

Study locations

55 sites
  • eStudySite
    La Mesa, California 91942, United States
  • Linda Vista Health Care Ctr
    San Diego, California 92111, United States
  • My Preferred Research
    Miami, Florida 33155, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Foot & Ankle Center of Illinois
    Springfield, Illinois 62704, United States
  • Velocity Clinical Research Rockville
    Rockville, Maryland 20854, United States
  • Amicis Centers of Clinical Research
    St Louis, Missouri 63128, United States
  • DM Clinical
    Albuquerque, New Mexico 87106, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Clinical Res Collaborative
    Cumberland, Rhode Island 02864, United States
  • DM Clinical
    Houston, Texas 77081, United States
  • Radiance Clinical Research
    Lampasas, Texas 76550, United States
  • DM Clinical Research
    San Antonio, Texas 78207, United States
  • DM Clinical
    San Antonio, Texas 78207, United States
  • Velocity Clinical Research Portsmouth
    Suffolk, Virginia 23435, United States
  • G.A. Research Associates Ltd.
    Moncton, New Brunswick E1G 1A7, Canada
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Centricity Clinical Research Burlington
    Burlington, Ontario L7M 4Y1, Canada
  • Centricity Research Etobicoke Endocrinology
    Etobicoke, Ontario M9R 4E1, Canada
  • Premier Clinical Trial Research Network (PCTRN)
    Hamilton, Ontario L8L 5G4, Canada
  • Diabetes Heart Research Centre
    Toronto, Ontario M6G 1M2, Canada
  • Ctr de Med Metab de Lanaudiere
    Terrebonne, Quebec J6X 4P7, Canada
  • Aarhus Universitetshospital, Steno Diabetes Center Aarhus
    Aarhus N, 8200, Denmark
  • Steno Diabetes Center Nordjylland
    Gistrup, 9260, Denmark
  • Steno Diabetes Center Copenhagen
    Herlev, 2730, Denmark
  • Kolding Sygehus Karkirurgi
    Kolding, 6000, Denmark
  • Steno Diabetes Center Odense
    Odense C, 5000, Denmark
  • Les Hopitaux de Chartres-Hopital Louis Pasteur
    Le Coudray, 28630, France
  • Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu
    Le Creusot, 71200, France
  • Aphp-Hopital La Pitie Salpetriere
    Paris, 75013, France
  • Centre Hospitalier Universitaire de Bordeaux-Hopital Haut Leveque
    Pessac, 33600, France
  • Centre de Recherche Clinique Portes Du Sud
    Vénissieux, 69200, France
  • Haukeland Universitetssykehus
    Bergen, 5021, Norway
  • Sykehuset Innlandet HF Hamar
    Hamar, 2318, Norway
  • Oslo universitetssykehus, Ullevål
    Oslo, 0450, Norway
  • Stavanger Universitetssykehus, Helse Stavanger HF
    Stavanger, NO-4011, Norway
  • Hospital Nisa Sevilla Aljarafe (To be inactivated when NN9388-7864 is in closing status)
    Castilleja de la Cuesta, Andalusia 41950, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Complejo Hospitalario Universitario A Coruña
    A Coruña, 15006, Spain
  • Hospital Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, 39008, Spain
  • H. Infanta Luisa_Endocrino y Obesidad
    Seville, 41010, Spain
  • Tameside General Hospital
    Ashton-under-Lyne, Greater Manchester OL6 9RW, United Kingdom
  • Ipswich Hospital - Diabetes
    Ipswich, IP4 5PD, United Kingdom
  • Aintree University Hospital
    Liverpool, L9 7AL, United Kingdom
  • St Pancras Clinical Research
    London, EC2Y 8EA, United Kingdom
  • King's College Hospital - Renal
    London, SW9 8RR, United Kingdom
  • Manchester Royal Infirmary - Diabetes
    Manchester, M13 9WL, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jun 2026, 16 months.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Jan 29, 2025
StartActual
Jan 29, 2025
Primary completionActual
Jun 26, 2026
CompletionActual
Aug 5, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06797869
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Jan 29, 2025
Primary completion
Jun 26, 2026
Completion
Aug 5, 2026
Last update
Sep 10, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion